Trial Profile
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b in Patients With Locally/Regionally Advanced/Recurrent Melanoma: Safety, Efficacy and Biomarker Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Interferon alpha-2a (Primary) ; Pembrolizumab (Primary)
- Indications Cancer metastases; Malignant melanoma
- Focus Adverse reactions
- 22 Mar 2021 Results (data cutoff date: 2 Oct 2019) assessing safety and efficacy published in the Clinical Cancer Research
- 22 Feb 2021 Status changed from active, no longer recruiting to completed.
- 19 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020.